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ABSTRACT 
Background & Aims: Little is known about the natural course of nonalcoholic fatty 
liver disease (NAFLD) with advanced fibrosis. We describe long-term outcomes and 
evaluate the effects of clinical and histologic parameters on disease progression in 
patients with advanced NAFLD.   
 
Methods: We conducted a multi-national study of 458 patients with biopsy-confirmed 
NAFLD with bridging fibrosis (F3, n=159) or compensated cirrhosis (222 patients with 
Child-Turcotte-Pugh [CTP] scores of A5 and 77 patients with scores of A6), evaluated 
from April 1995 through November 2013 and followed until December 2016, death, or 
liver transplantation at hepatology centers in Spain, Australia, Hong Kong, and Cuba. 
Biopsies were reevaluated and scored; demographic, clinical, laboratory, and pathology 
data for each patient were collected from the time of liver biopsy collection. Cox 
proportional and competing risk models were used to estimate rates of transplant-free 
survival and major clinical events and to identify factors associated with outcomes. 
 
Results: During a mean follow-up time of 5.5 years (range, 2.7–8.2 years), 37 patients 
died, 37 received liver transplants, 88 had initial hepatic decompensation events, 41 
developed hepatocellular carcinoma (HCC), 14 had vascular events, and 30 developed 
non-hepatic cancers. A higher proportion of patients with F3 fibrosis survived 
transplant-free for 10 years (94%; 95% CI, 86–99) than of patients with cirrhosis and 
CTP-A5 (74%; 95% CI, 61–89) or CTP-A6 (17%; 95% CI, 6–29). Patients with 
cirrhosis were more likely than patients with F3 fibrosis to have hepatic 
decompensation (44%; 95% CI, 32–60 vs 6%, 95% CI, 2–13) or HCC (17%; 95% CI, 
8–31 vs 2.3%, 95% CI, 1–12). The cumulative incidence of vascular events was higher 
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in patients with F3 fibrosis (7%; 95% CI, 3–18) than cirrhosis (2%; 95% CI, 0–6). The 
cumulative incidence of non-hepatic malignancies was higher in patients with F3 
fibrosis (14%; 95% CI, 7–23) than cirrhosis (6%; 95% CI, 2–15). Death or 
transplantation, decompensation, and HCC were independently associated with baseline 
cirrhosis and mild (<33%) steatosis whereas moderate alcohol consumption associated 
with these outcomes only in patients with cirrhosis. 
Conclusions: Patients with NAFLD cirrhosis have predominantly liver-related events 
whereas those with bridging fibrosis have predominantly non-hepatic cancers and 
vascular events.   
KEY WORDS: Nonalcoholic steatohepatitis; cryptogenic cirrhosis; gastroesophageal 
varices; competing risk analysis. 
Word count: 366 words 
6 
 
INTRODUCTION 
Non-alcoholic fatty liver disease (NAFLD) is one of the leading causes of 
hepatocellular carcinoma (HCC), end-stage liver disease and liver transplantation 
worldwide.1-5 Its prevalence is growing in parallel with the global epidemics of obesity 
and type 2 diabetes.6 Although its evolution towards liver-related complications is 
relatively slow, approximately one third of NAFLD patients may eventually progress to 
nonalcoholic steatohepatitis (NASH), of whom 20% will develop hepatic fibrosis with a 
risk for extrahepatic complications, cirrhosis, and liver failure. 7-12  
A number of well-designed retrospective studies detailing the long-term mortality 
of histologically confirmed NAFLD have been published. 13-18 These reinforce the 
importance of fibrosis as the most robust determinant of all-cause and liver-related 
mortality; a dose-dependent effect has been observed across all fibrosis stages (from 
stage 1 to 4), however, the risk of liver-related mortality is exponentially increased 
while transitioning from stage 2 to 4. 14, 19, 20 Patients with bridging fibrosis and 
cirrhosis have the highest risk of liver-related death, however due to the high prevalence 
of co-morbid cardio-metabolic risk factors such as diabetes and obesity, they are also at 
risk of developing major vascular events and non-hepatic malignancies. Unfortunately, 
earlier studies have included small numbers of patients with advanced fibrosis, which 
makes it difficult to understand the true risk on the full spectrum of major 
complications. This study sought to investigate the long-term overall transplant-free 
survival and cumulative incidences of major clinical events (hepatic decompensation, 
HCC, stroke or ischemic heart disease and non-hepatic malignancies) in a large cohort 
of biopsy-confirmed NAFLD with advanced fibrosis followed for 10 years, and to 
identify potential predictors for outcomes.     
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METHODS 
The NAFLD progression consortium (NPC) is an international initiative which includes 
tertiary academic centers with recognized experience and participation in studies related 
to the natural history of NAFLD. The main objective is to gather and analyse 
information of existing prospectively collected data of patients with biopsy-proven 
NAFLD. 
Study design and participants.  
A consortium of researchers from tertiary referral centers in Europe, Asia, Australia and 
America was created. Each center had independently developed a prospective data 
registry of consecutive biopsy-proven NAFLD patients with at least 25 or more patients 
with advanced fibrosis with a minimum of 1 year of follow-up. All subjects were 
recruited from Hepatology clinics at each center following referral from community 
physicians and were enrolled by the local investigator.  Each center had local approval 
from their Institutional Review Board and signed informed consent was obtained from 
each patient. Some patients included in this cohort have been part of other papers 
published previously.15 
Liver biopsies were performed in the presence of fatty liver detected by imaging 
and/or, persistently increased levels of aminotransferase for at least 6 months and/or risk 
factors for advanced disease (e.g. metabolic syndrome, age > 45 years, obesity, 
diabetes) and/or suspected advanced fibrosis or cirrhosis as determined by abnormal 
laboratory (low platelet count, etc.) and imaging (US, CT or MRI) tests.  
Patients were excluded if they had one of the following: significant alcohol intake 
(> 20 g per day for men and > 10 g per day for women during the last two years or 
during follow-up), secondary causes of liver diseases, including viral, autoimmune, 
drug-induced, cholestatic, genetic or metabolic, secondary causes of NAFLD, history of 
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bariatric surgery, significant body weight reductions (>5%) via lifestyle changes in the 
last year, type 1 diabetes, known sero-positivity for HIV, Child-Turcotte-Pugh (CTP) 
score ≥ 7 or history of hepatic decompensation, MELD score ≥ 15 (excluding values 
dependent of high levels of creatinine), albumin <3.0 g/dL, total  bilirubin > 3.0 mg/dL, 
INR >2, platelets <100,000 mm3, concomitant diseases with reduced life expectancy,  
evidence of HCC at enrollment or within 6 months of follow-up and inability to provide 
informed consent. 
A total of 512 subjects aged 18 to 80 years with histologically-confirmed NAFLD 
and advanced fibrosis (F3/F4) were evaluated from April 1995 to November 2013; 458 
fulfilled eligibility criteria and were followed until December 2016, or death or liver 
transplantation (supplementary Figure 1).  
Histological Assessment 
In all participant centers, biopsies were reevaluated and scored by local pathologists 
using the NASH-CRN scoring system and fibrosis (F) stages, 21, 22 independent of the 
original histology report. Only reports of repeated histological assessment were 
considered in our analyses. Pathologists were unaware of the patients’ clinical and 
laboratory features. A threshold of at least 5% of hepatocytes showing steatosis was 
necessary for histological confirmation of NAFLD. Since hepatocellular injury may 
reduce or disappear during advanced fibrosis or cirrhosis, presence of at least ballooning 
and/or lobular inflammation was required for confirming NASH.21-23 For all biopsy 
samples, the NAFLD activity score (NAS) and their individual components were scored 
as follow: steatosis (0-3), lobular inflammation (0-3) and hepatocellular ballooning (0-
2). The stage of fibrosis was assessed from 0 to 4 (1: perisinusoidal or portal/periportal 
only; 2: perisinusoidal and periportal; 3: bridging fibrosis; 4 cirrhosis), but only F3 and 
F4 stages were considered for analysis in the present study.   
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Although reproducibility studies have shown good or excellent pathological 
agreement for steatosis grades (kappa, 0.79) or extent of fibrosis (kappa, 0.84), we 
sought to confirm the diagnostic accuracy and consistency of our initial pathological 
evaluations.21 To do so, 48 random samples were selected from overall cohort and sent 
for central reading and scoring to Dr. Anthony Chan at The Chinese University of Hong 
Kong who was blinded to all study information, including previous pathological reports.  
Interobserver variation among pathologist was evaluated by kappa statistics. We 
observed high inter-rater agreement for stage of fibrosis (κ ranging from 0.80-1) and 
extent of steatosis (κ ranging from 0.71-0.85) Agreement was moderate for grading 
lobular inflammation (κ ranging from 0.44-0.63) and ballooning (κ ranging from 0.53-
0.75).  
Data collection, follow-up and events assessment 
Demographic, clinical, laboratory, and pathological data for each patient were collected 
at the same time of liver biopsy.  The follow-up period began on the date of biopsy and 
ended on the date of the last visit, death, or transplant. All patients were evaluated every 
3-6 months according to local clinical standards of care and the occurrence of death or 
liver transplantation were the primary outcomes of interest. Patients lost to follow-up 
(n=4) were censored at the last date known to be alive.  
A detailed medical history and physical examination along with standard 
laboratory tests were routinely performed at each follow-up visit. This included 
assessment of alcohol consumption, 24 smoking, development of diabetes or co-morbid 
malignancy or vascular disease. This data was collected prospectively and 
retrospectively following an extensive review of the patient medical record, clinic letters 
and laboratory results. Six-monthly liver ultrasound (US) and serum α-fetoprotein 
determinations were obtained to screen for HCC if the patient had cirrhosis. Diagnosis, 
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screening and treatment of hepatic and non-hepatic (e.g., cardiovascular disease, cancer, 
etc.) clinical events were implemented according to local standards-of-care. Given the 
absence of approved treatments for NAFLD, therapeutic recommendations were similar 
in all participant centers and included dietary modifications and/or increased physical 
activity.  
The development of major clinical events over time was defined as follows: (1) 
hepatic decompensation defined as the first occurrence of ascites (identified by 
abdominal US), or upper gastrointestinal bleeding secondary to portal hypertension 
(confirmed by endoscopy in the presence of gastroesophageal varices or hypertensive 
gastropathy) or hepatic encephalopathy (established by clinical parameters, 
neuropsychological tests, or electroencephalogram); (2) HCC diagnosed by dynamic 
contrast-enhanced imaging methods (CT scan or MR) according to standard criteria25 or 
biopsy; (3) major vascular events defined as the development of a new episode of 
cardiovascular (myocardial infarction, hospitalization for congestive failure or unstable 
angina, aneurysm dissection, or cardiac arrest) or cerebrovascular (ischemic or 
hemorrhagic stroke) disease; (4) non-hepatic malignancy (any other than HCC) 
excluding non-melanoma skin cancers. Each of these events was recorded when first 
seen, and recurrence of the same complication or occurrence of a new event pertaining 
to the same category was not included.  
Statistical analysis 
Time to any clinical outcome was computed as the number of years from 
enrollment to the date of the initial clinical outcome. Cox proportional hazard models 
were performed to estimate the adjusted hazard risks and identify independent 
predictors of death or transplant.  
11 
 
The cumulative incidence of secondary outcomes (first event of hepatic 
decompensation, HCC, major vascular events and non-hepatic malignancies) were 
calculated in the presence of competing risks events (another event has occurred, which 
precludes or modifies the occurrence of the event of interest).26 To estimate effects of 
covariates on secondary outcomes, univariate and multivariable competing risk 
regression models for the sub-distribution hazards were performed according to the 
method of Fine and Gray.26, 27  The strength of the association between each covariate 
and the outcome of interest was assessed using the subhazard ratio (sHR) with 95% CI.  
Transplant-free survival rates and cumulative incidences of secondary outcomes 
in all cases were adjusted by center and calendar year of patient recruitment; Figures 1-3 
represent adjusted predictions.   
As long-term clinical outcomes may be influenced by the severity of fibrosis and 
liver function, analyses were stratified by fibrosis stage (F3 vs. F4) and CTP score 
(class A5 vs. A6). 
We further reported the annualized incidence rates with their 95% confidence 
intervals for all outcomes. These rates were calculated by dividing the number of 
patients with a defined event by the number or person-years for which the subjects were 
followed and then multiplied by 100. Missing values were imputed by applying the 
multiple imputations method where missing data are imputed or replaced with a set of 
plausible values.28  
All confidence intervals, significance tests, and resulting P values were two-sided, 
with an alpha level of 0.05.  Statistical analyses were performed using STATA software, 
release 13.  
 
RESULTS 
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Baseline Characteristics 
Table 1 summarizes overall features of the study population. A total of 458 subjects 
were included, of which 159 (35%) and 299 (65%) had bridging fibrosis and cirrhosis, 
respectively. Most of cirrhotic patients were CTP-A5 (74%). The patients’ mean age 
was 55.9 years and 52% were women. There was a preponderance of white race (81%), 
mostly Hispanic (56%). The mean BMI was 33.2 kg/m2 and about two thirds had type 2 
diabetes (67%) or hypertension (61%). The mean MELD score was 7.7 ± 2.6 and 
gastroesophageal varices were present in 92 (20%) individuals. Overall, 39 (9%) and 22 
(5%) patients had a previous history of vascular diseases and malignant neoplasms, 
respectively. The mean NAS was 4.2 ± 1.9 and 199 (43%) subjects had a NAS ≥ 5. The 
median biopsy length and portal tracts were 18 mm (IQR: 15-23) and 9 (IQR: 8-11), 
respectively. Three-hundred and ninety-four (86%) biopsy samples had a length of at 
least 15 or more millimeters and 123 (27%) had less than 10 portal tracts. 29, 30 As 
shown in Table 1, clinical and biochemical data related to severity of liver disease were 
worse in cirrhotic patients and more severe in those with CTP class A6 than those with 
A5. Elevated levels of INR (1.7-2) but mainly bilirubin (2-3 mg/dl) or albumin (3.0-3.5) 
would explain the main differences found between compensated patients with CTP A5 
vs A6 (supplementary Table 1). Although cirrhotic patients tended to have a higher 
mean 10-y risk score for heart/stroke disease31 (F4-A5: 13.9 vs. F4-A6: 13.5 vs. F3: 
11.4, P=0.12), other well-recognized risks factors for vascular disease such as total 
cholesterol and LDL cholesterol levels and systolic/diastolic blood pressures were lower 
than in non-cirrhotic patients (all P<0.05). Interestingly, cirrhotic patients with CTP-A6 
had less inflammation and steatosis (steatosis < 33% [53, 69%], none or few lobular 
inflammation [69, 77%] and none or few ballooned cells [64, 83%)] than subjects with 
F3 or F4-A5, (P<0.01). Supplementary Table 2 summarizes key baseline 
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characteristics between countries. Only BMI and waist circumference values were 
significantly different (lowest) in cohorts from Hong Kong and Cuba as compared with 
the remaining cohorts after adjustments for fibrosis severity and CTP scores 
(supplementary appendix and Table 1).  
 
Time-Dependent Characteristics 
Eleven (17%) of the 66 patients with a baseline level of moderate (between 1-70 g/week 
for women and 1-140 g/week for men) alcohol intake became abstinent over the course 
of follow-up. No heavy or new-onset drinkers were recorded during follow-up. 
New-onset type 2 diabetes was detected in 21 (14%) of 153 subjects without diabetes at 
baseline, with no significant difference observed between patients with bridging fibrosis 
and cirrhosis (P=0.17). Of 77 patients reported as current smokers at baseline, 62 were 
still smoking while all non-smoker participants remained as non-smokers over time.     
Overall survival without liver transplantation 
The overall mean follow-up period was 5.5 years (range, 2.7-8.2). Overall causes of 
death, occurrence of major clinical events and their annualized rates are summarized in 
Table 2, 3 and supplementary appendix, Table 3.  
During follow-up, 74 patients died (37 [8%]) or were transplanted (37 [8%]). The 
major causes of death were liver-related (F4-A6: 18 vs. F4-A5: 11 vs. F3: 2) and 6 were 
non-liver-related (F4-A6: 0 vs. F4-A5: 4 vs. F3: 2). Most liver-related deaths were 
attributable directly to complications of end-stage liver disease, where hepatorenal 
syndrome and HCC were the commonest causes. Three (50%) of six non-liver-related 
deaths were from vascular events. Hepatic decompensation (26 patients, 70%) was the 
main indication for liver transplantation followed by HCC (6 subjects [16%]) and the 
combination of end-stage renal-hepatic failure (5 patients [14%]). Ten-year overall 
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transplant-free survival rate was 68% (95% CI: 53-75); 94% (95% CI: 86-99) in F3, 
74% (95% CI: 61-89) in F4-A5 and 17% (95% CI: 6-29) in F4-A6 patients (P<0.01), 
which is equivalent to annualized mortality/liver transplantation rates of 0.5, 2.1 and 
11.1 per 100 person-years, respectively, P<0.01 (Figure 1 and Table 3).  
 
Cumulative incidence of a first major clinical event 
The 10-year cumulative rates for a first major clinical event were notably higher 
in cirrhotic patients with CTP-A6 (92%, 95% CI: 80-99) than subjects with F4-A5 
(60%, 95% CI: 48-73) and F3 (30%, 95% CI: 21-49), P<0.01 (supplementary 
appendix, Figure 4). Hepatic decompensation (85% and 59%) and HCC (15% and 
19%) were the commonest first events seen in cirrhotic patients with CTP-A6 and A5 
respectively, in contrast to non-hepatic malignancies (38%) and vascular events (35%) 
that were the most frequently observed in F3 patients (Table 2). 
Liver-related events 
During 10 years of follow-up, 88 (19%) and 41 (9%) patients developed an 
episode of hepatic decompensation or HCC, respectively. Ascites (62 of 88, 70%) and 
variceal bleeding (21 of 88, 24%) were the most common causes of decompensation. At 
the time of HCC diagnosis, 31 (76%) of 41 were detected in very early or early stages, 
and of them, 22 were treated with curative treatments (ablation, n=19 or resection, n=3) 
and 9 with liver transplant. Six and four patients were diagnosed in intermediate and 
advanced stages and were treated with TACE or sorafenib respectively. Six of them 
died due to HCC. Half of patients with HCC development (22 of 41, 51%) had a 
previous episode of hepatic decompensation during follow-up.        
Cirrhotics were more likely to develop hepatic decompensation (44%, 95% CI: 32-60) 
and HCC (17%, 95% CI: 8-31) than those with bridging fibrosis (decompensation: 6% 
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[95% CI: 2-13], HCC: 2.3% [95% CI: 1-12]), P<0.01. Among cirrhotic patients, CTP-
A6 showed highest CIs of hepatic decompensation (84%, 95% CI: 72-95) and HCC 
(37%, 95% CI: 22-49) as compared to CTP-A5 (decompensation: 30%, 95% CI: 19-46; 
HCC: 16%, 95% CI: 10-26), P<0.01. The annualized rates for hepatic decompensation 
and HCC were 15.6 and 4.7 in F4-A6, 3.3 and 1.8 in F4-A5 and 0.6 and 0.2 in F3 
subjects, respectively (Figure 2A-B and Table 3).     
Major vascular events and non-hepatic malignancies 
A total of 14 (3%) vascular events occurred over time, of which 10 (71%) and 4 
(29%) were related to cardiac and cerebrovascular diseases, respectively. Only 3 (21%) 
patients died due to vascular events. The cumulative incidence of developing any 
vascular event was considerably higher in subjects with F3 (7%, 95% CI: 3-18) than F4 
(2%, 95% CI: 0-6), adj. Fine and Gray P<0.01 and no difference was found among 
cirrhotic patients with CTP A5 and A6 (Figure 2C). 
As shown in Table 2, 30 (7%) patients developed at least one non-hepatic 
malignant neoplasm. The most frequent neoplasm was colorectal cancer seen in 15 
cases (50%), followed by skin (6, 20%), breast (3, 10%), and uterine (2, 7%) cancers. 
Two patients died due to metastatic colorectal cancer. After excluding skin cancers due 
to low causality relationship with NAFLD, the cumulative incidence of non-hepatic 
malignant neoplasia was numerically higher in F3 subjects (14%, 95% CI: 7-23) than 
F4-A5 (7%, 95% CI: 2-15) and F4-A6 (4%, 95% CI: 1-10) individuals, however, no 
significant differences were observed among groups, adj. P=0.10 (Figure 2D). 
Predictors of overall mortality and major clinical outcomes 
Demographic, clinical and biochemical predictors  
Univariate association between potential predictors and transplant-free survival 
and liver-related outcomes is shown in supplementary Table 4.  
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At multivariable analysis (Table 4), age and male sex were positively associated 
with worse survival (HR for age: 1.03, HR for male: 1.87) and greater incidence of 
HCC (sHR for age: 1.05, sHR for male: 7.28). Current smoking was also associated 
with a higher risk of mortality (HR: 1.74) and HCC (sHR: 2.11). Type 2 diabetes was a 
robust predictor of poor transplant-free survival (HR: 3.33) and liver-related outcomes 
(sHR for decompensation: 2.82, sHR for HCC: 4.72).  
Gastroesophageal varices at baseline was associated with worse survival (HR: 
2.19) and higher rates of hepatic decompensation (sHR: 1.99) and MELD score 
remained an important predictor of long-term survival (HR: 1.10), Table 4. Other 
factors strongly related with severity of liver disease such as albumin, INR, bilirubin, 
and platelets were also associated with transplant-free survival and decompensation. 
Table 4 summarizes association between potential predictors, transplant-free survival 
and liver-related outcomes.    
        Interestingly, moderate alcohol consumption was found to increase risk of death or 
transplant (HR 2.3, 95% CI: 1.32-4.02), decompensation (HR: 1.65, 95% CI: 1.01-2.61) 
and HCC (HR 3.22, 95% CI: 1.64-6.32) among cirrhotic patients even after adjustments 
by CTP score and other potential confounders, all P<0.05. No association was found 
between liver-related outcomes and moderate alcohol intake among patients with 
bridging fibrosis. Likewise, no relationship was observed between non-hepatic 
outcomes and alcohol consumption. Supplementary Table 5 and Figure 5 A-C 
illustrate the association between alcohol consumption and study outcomes.  
Histological predictors 
Overall, cirrhosis negatively affected survival rates (HR: 5.99) and liver-related 
outcomes (sHR for decompensation: 6.55; sHR for HCC: 6.52), but was associated with 
lower frequency of vascular events (sHR: 0.25). Although lower scores of steatosis, 
17 
 
lobular inflammation and ballooning were inversely associated with fibrosis severity 
and CP score (Table 1), only steatosis < 33% was consistently associated with worse 
survival (HR: 2.56) and liver-related events (sHR for decompensation: 2.64, sHR for 
HCC: 2.21) even after adjustments for potential demographic and clinical confounders 
(supplementary Table 6). Given the magnitude of the association between steatosis < 
33% and severity of liver disease, we explored the relative importance of combining 
both variables on major clinical outcomes in cirrhotic patients. As shown in Figure 3A, 
patients within the same class of CTP and steatosis < 33% had worse survival than those 
with steatosis ≥ 33%, P<0.01. However, the “protective” association of steatosis ≥ 33% 
on development of hepatic decompensation was limited to subjects with CTP-A5, 
P<0.01 (Figure 3B). HCC rates were higher in patients with steatosis < 33% 
irrespective of CTP score class, P<0.01 (Figure 3C). While an unadjusted analysis 
showed higher rates of HCC in subjects with CTP-A6 compared with CTP-A5, no 
significant differences were observed between these two subgroups after adjusting by 
steatosis < 33%, sHR: 0.56. We did not find any association between steatosis severity 
and vascular event rates (data not shown). 
 
Predictors of major vascular events 
Regarding major vascular events, older age (sHR: 1.05), diabetes (sHR: 2.15), 
baseline BMI (sHR: 1.07) and LDL cholesterol levels (sHR: 1.06) were independently 
associated with the occurrence of any major vascular event over time (supplementary 
Table 7). No significant association was found between baseline 10-y heart/stroke risk 
score, moderate alcohol consumption or smoking and the incidence of vascular events, 
although the number of vascular events were relatively low.   
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DISCUSSION 
This study identifies new information on the clinical course of NAFLD patients 
with advanced fibrosis based on three stages of disease with distinctly different 
outcomes.  
The current data shows that among NAFLD patients with advanced fibrosis, those 
with cirrhosis are at a significantly greater risk for hepatic decompensation, HCC and 
death or liver transplantation as compared to those with bridging fibrosis. Among 
cirrhotic patients, hepatic decompensation (70%) was the most commonly identified 
initial clinical event, followed by HCC development (17%); both were linked to 
profound effects on survival rates and the requirement for liver transplantation. In 
contrast, patients with bridging fibrosis showed a more benign clinical course with 
higher transplant-free survival (94%) and less liver-related complications than those 
with cirrhosis. Vascular events (35%) and non-hepatic malignancies (38%) accounted 
for two thirds of all major initial events in these subjects. Although overall mortality 
was significantly lower in bridging fibrosis, 50% (2 of 4) of deaths were directly 
attributed to vascular events or non-hepatic cancers. In contrast, patients with cirrhosis 
were at significantly lower risk for non-liver related complications (14 [12%] of 115 
initial events) and deaths (4 [12%] of 33).  
Among Childs class A cirrhotics, hepatic outcomes were dramatically worse 
among those with CTP-6 versus CTP-5, despite both groups being compensated at 
baseline. Results of previous studies have confirmed that patients with significant or 
advanced fibrosis (F2-F3) are at higher risk of vascular events and cancers as compared 
with subjects without significant fibrosis (F0-F1). Taken as a whole, previous and 
current findings highlight the importance of underlying fibrosis stage in determining 
clinical outcomes and cause-specific mortality.7, 14, 32, 33  
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The co-existence of obesity, metabolic syndrome, and diabetes among advanced 
stage NAFLD patients can trigger cardiovascular events and cancers. In this regard, the 
relatively low rates of vascular events and non-hepatic malignancies was not anticipated 
and is noteworthy. While bridging fibrosis progresses to cirrhosis and to impairment of 
liver function, blood pressure, cholesterol levels and body weight tend to decrease (as 
shown in Table 1) which may partly explain the lower rates of vascular events in 
cirrhotic patients. However, this finding does not easily explain the low rate of non-
hepatic cancers. Another potential explanation for our observations is that higher liver 
related competing mortality or transplantation in cirrhotic patients may have precluded 
the development of vascular events and non-hepatic cancers over time. 
Although fibrosis stage was biopsy-confirmed in all patients, 7 (4%) with bridging 
(F3) fibrosis had gastroesophageal varices at study entry. This suggests that there could 
be some misclassification and underscores the limitations inherent with liver biopsy. 
Notably, the recent Baveno consensus recommended the term of compensated advanced 
chronic liver disease (cACLD) which may include bridging fibrosis and cirrhosis and 
identifies patients at risk of developing clinically significant portal hypertension. 34 
cACLD is suspected with a high liver stiffness measurement and confirmed with 
biopsy, endoscopy or hepatic venous pressure gradient assessment. 
Another key finding was that the outcomes among cirrhotics were worse in 
patients with CTP class A6 as compared with A5. CTP-A6 patients were at highest risk 
of hepatic decompensation, HCC and death or transplant. At 10 years, three quarters of 
CTP-A6 patients had either died or required a liver transplant compared to one in five 
CTP-A5 patients and only one in 25 patients with baseline bridging fibrosis. 
Interestingly, a low albumin was the commonest biochemical abnormality in CTP- A6 
patients in the absence of clinically manifest decompensation. While patients with 
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bridging fibrosis have lower probabilities of liver-related outcomes within the first 10 
years of follow-up, the greater likelihood of vascular events and non-hepatic 
malignancies suggests surveillance and prevention strategies for these outcomes should 
be prioritized as part of their management. In contrast, compensated cirrhotic patients, 
and most importantly those with CTP-A6 had the worst survival, mandating close 
monitoring to prevent and control liver-related events. These findings are also 
particularly relevant for the design and interpretation of clinical trials. 
Previous long-term follow-up studies have reported increased rates of liver-related 
outcomes among NAFLD patients with cirrhosis, 15, 35-38, however, the time-course of 
events were not reported, one of them included solely decompensated cirrhotic 
patients35, no major comparisons were performed for all outcomes among F3 and F4 
patients15, and all studies were underpowered to detect robust predictors for death,15 
decompensation15 or HCC15, 35. In the study of Bhala and colleagues, 7.7% and 2.4% of 
patients with F3 or F4 developed hepatic decompensation or HCC during an average of 
85.6 months.15 Likewise, Ascha, et al. reported that NASH-cirrhotic patients are at 
increased risk of developing HCC, and the annual cumulative incidence of HCC was 
found to be 2.6% in patients NASH-cirrhosis compared with 4.0% in patients with 
HCV-related cirrhosis.35  
In this study, HCC development appeared mostly in cirrhotic patients, being less 
frequent in subjects with bridging fibrosis. The presence of higher rates of HCC in 
cirrhotics with CTP-A6 suggest the need for greater vigilance and perhaps more 
rigorous screening approaches.39, 40  
Our data interestingly suggested that steatosis < 33% is significantly associated 
with a higher risk of death and liver-related complications including HCC, and this 
effect was particularly marked in cirrhotic patients even after adjustments for potential 
21 
 
confounders such as CTP score. Patients within the same class of CTP with steatosis < 
33% had shorter survival and higher risk of decompensation and HCC than those with 
steatosis ≥ 33%. As shown in supplementary Table 8, steatosis < 33% was associated 
with lower BMI, marked impairment in liver function tests and reduced values of serum 
lipids which have been associated with liver dysfunction and malnutrition in cirrhotic 
patients. Data from previous clinical studies suggest that cirrhotic-NASH patients often 
have a significant reduction in hepatic fat, a phenomenon known as “burnt-out” NASH. 
Increased utilization of fat stores (including in liver) due to an increased catabolic state, 
diversion of insulin and nutrients from the liver due to portal hypertension and increased 
levels of adiponectin have been postulated as potential pathways to explain the reduced 
levels of hepatic lipids in these subjects.41 Van der Poorten, et al. found that in NASH 
patients with advanced fibrosis, high circulating adiponectin 42 were associated with 
hepatic fat loss irrespective of metabolic and liver dysfunction.41 In another interesting 
study, adiponectin levels were significantly elevated in cirrhotic patients and the level of 
adiponectin increased proportionately with the Child-Pugh score.43 Adiponectin levels 
have been inversely associated with the risk of developing cancer and coronary heart 
disease 44-46. Thus, the hypothesis that hyperadiponectinemia seen in NASH-cirrhosis 
could be protective for HCC and coronary heart disease risk needs to be explored. Our 
data lends support to this hypothesis of steatosis < 33% being an indirect marker of liver 
disease severity, hyperadiponectinemia and probably of malnutrition in compensated 
NASH cirrhosis.  
Our findings support previous studies indicating that older age, male gender and 
current smoking are common risk factors for HCC development.47-49  
Previous epidemiological data suggests that slight or moderate alcohol intake 
may have favorable hepatic effects among NAFLD patients, 24, 50 However, a recent 
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longitudinal study that examined the association of alcohol consumption and the 
histological evolution of NAFLD histology in patients with paired biopsies found that 
modest alcohol consumption was associated with less improvement in NASH and 
steatosis compared to non-alcohol intake 51. The influence on liver-related outcomes 
among NAFLD patients however has not been examined in longitudinal studies. Our 
data indicates that moderate alcohol consumption among compensated NASH cirrhotic 
patients may exacerbate the progression of liver disease and increase the risk of hepatic 
decompensation, HCC and death. In compensated HCV-related cirrhosis, moderate 
alcohol consumption has also been linked to increased risk of HCC.52 In contrast to 
findings in the general population, moderate alcohol use may not reduce the risk of 
cardiovascular events in patients with NAFLD.53 Thus, NAFLD patients, in particular 
those with cirrhosis, should be strongly advised to avoid any alcohol intake.          
Although a low number of vascular events occurred over time, we sought to 
identify its potential predictors. Diabetes, larger BMI, older age and higher LDL 
cholesterol levels were positively associated with the occurrence of ischemic heart and 
cerebrovascular diseases. These findings suggest that intensive control of these and 
other well-recognized risk factors for vascular disease may have been implemented, 
irrespective of liver disease severity.  
It’s important to address some limitations of this study. Firstly, we presented the 
cumulative incidence of each outcome occurring from each stage (F3 vs. F4 with CTP-
A5 vs. F4 with CTP-A6) as defined at study enrollment, without accounting for 
transition across stages over time. Second, prospective information on dynamic changes 
in metabolic and lipid parameters as well as pharmacological interventions for obesity-
related comorbidities and the compliance to standardized protocols for diagnosing and 
treating clinical events were not documented. Third, our study failed to obtain central 
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pathological reading of all liver samples. Lastly, our cohort was derived from tertiary 
referral centers and consisted of patients who underwent liver biopsy, and thus may be 
biased towards more severe disease. 
 
CONCLUSION 
NAFLD patients with biopsy-proven cirrhosis have a higher mortality and liver-
related complications than those with bridging fibrosis, whereas vascular events and 
non-hepatic malignancies are the commonest complications in those with bridging 
fibrosis. Patients with diabetes were at high risk group for both liver and vascular 
outcomes. Moderate alcohol consumption significantly increases risk of hepatic 
decompensation, HCC and liver-related death in cirrhotic patients. Steatosis severity 
was inversely related to liver disease severity and constituted an important predictor of 
survival and hepatic outcomes.  
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TABLES 
Table 1. Baseline characteristics.  
Variable 
Overall 
N=458 
Bridging 
fibrosis 
n=159 
Cirrhosis 
CTP A5  
n=222 
Cirrhosis 
CTP A6 
n=77 
P  
value 
Age (y) 55.9 ± 11.2 54.2 ± 10.7 56.6 ± 11.8 57.4 ± 10.4 .04 
Male, n (%) 218 (48) 79 (50) 99 (46) 40 (52) .43 
Race/ethnicity     <.01 
  Hispanic White 256 (56) 76 (48) 123 (55) 57 (74)  
  Non-Hispanic White 112 (24) 45 (28) 49 (22) 18 (23)  
  Asian 86 (19) 38 (24) 46 (21) 2 (3)  
  Black 4 (1) 0 (0) 4 (2) 0 (0)  
Former smoking, n (%) 59 (13) 25 (16) 24 (11) 10 (13) .73 
Current smoking, n (%) 78 (17) 26 (16) 39 (18) 13 (17) .84 
Alcohol consumption, n (%)     <.01 
Non-drinkers 392 (86) 142 (89) 192 (86) 58 (75)  
Moderate drinkers (1-70 g/week 
women, 1-140 g/week men). 
66 (14) 17 (11) 
30 (14) 
19 (25) 
 
BMI (kg/m2)    33.2 ± 8.6 35.1 ± 10.6 32.3 ± 7.1 31.6 ± 6.7 <.01 
Waist (cm) 106.6 ± 15.9 108.1 ± 15.9 106.1 ± 15.8 105.3 ± 15.7 .34 
MELD score 7.7 ± 2.6 6.6 ± 1.11 7.5 ± 2.29 10.8 ± 3.32 <.01 
Gastroesophageal varices, n (%) 92 (20) 7 (4) 49 (22) 37 (47) <.01 
History of hypertension, n (%) 281 (61) 97 (61) 136 (61) 48 (62) .98 
Systolic blood pressure (mm/Hg) 134.3 ± 17.2 137.5 ± 16 133.8 ± 15.9 129.4 ± 16.4 <.01 
Diastolic blood pressure (mm/Hg)  81.6 ± 10.5 83.5 ± 11.9 81.3 ± 9.2 78.8 ± 10.3 <.01 
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Type 2 diabetes, n (%) 305 (67) 93 (58) 156 (70) 56 (73) .03 
  Insulin, n (%) 111 (24) 24 (15) 62 (28) 25 (32) <.01 
  Metformin, n (%) 177 (39) 66 (42) 90 (41) 21 (27) .04 
  Sulfonylurea, n (%) 96 (21) 35 (22) 47 (21) 14 (18) .78 
  DDP-4 inhibitors, n (%) 20 (4) 12 (8) 6 (3) 2 (3) .23 
  SGLT2 inhibitors, n (%) 9 (2) 3 (2) 4 (2) 2 (3) .85 
  Glitazones, n (%) 15 (3) 8 (5) 6 (3) 1 (1) .42 
Vitamin E, n (%) 6 (1) 4 (3) 2 (1) 0 (0) .61 
ALT (U/L) 65.3 ± 47.4 70 ± 40.7 62 ± 46.3 64.9 ± 41.3 .51 
AST (U/L) 59.8 ± 43.5 56.9 ± 35.1 53.3 ± 36.3 85.5 ± 77.4 <.01 
AST/ALT ratio 1.04 ± 0.46 0.92 ± 0.47 1 ± 0.39 1.39 ± 0.49 <.01 
γ-Glutamyl transferase (U/L) 143.4 ± 109.2 142.6 ± 111.2 143.4 ± 99.4 145.2 ± 121.4 .99 
Ferritin (ng/ml) 370.5 ± 289.2 444.3 ± 135.5 352.1 ± 165.1 272.4 ± 113.9 .03 
Fasting glucose (mg/dl) 139.2 ± 62.2 126.1 ± 39.1 143.9 ± 61.2 152.7 ± 68.9 <.01 
HbA1c (%) 6.96 ± 1.89 6.66 ± 1.42 7.10 ± 2.1 7.15 ± 2.08 .04 
Fasting insulin (mIU/L) 21.4 ± 11.6 19.7 ± 8.9 21.6 ± 13.1 24.4 ± 11.5 .01 
HOMA-IR 8.2 ± 7.4 6.6 ± 4.4 8.7 ± 7.4 10.1 ± 8.4 <.01 
Cholesterol (mg/dl) 181.6 ± 52.2 192.1 ± 49.7 179.6 ± 51.6 165.6 ± 54.8 <.01 
HDL cholesterol (mg/dl) 44.7 ± 11.6 45.9 ± 11.8 44.7 ± 12.1 42 ± 9.1 .05 
LDL cholesterol (mg/dl) 104.7 ± 44.7 107.4 ± 42.6 105.8 ± 45.3 95.7 ± 46.6 .04 
Triglycerides (mg/dl)  167.3 ± 91.7 182 ± 113.2 161.6 ± 75.5 153.4 ± 81.1 .03 
Statin therapy, n (%) 110 (24) 42 (26) 55 (25) 13 (17) .26 
Total bilirubin (mg/dl) 0.83 ± 0.67 0.58 ± 0.21 0.75 ± 0.34 1.55 ± 0.88 <.01 
Albumin (g/dl) 4.16 ± 0.43 4.28 ± 0.34 4.19 ± 0.16 3.81 ± 0.57 <.01 
INR 1.09 ± 0.31 1.01 ± 0.04 1.04 ± 0.07 1.34 ± 0.37 <.01 
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Platelets (x 109/L)  184 ± 69 215 ± 67 181 ± 60 128 ± 51 <.01 
α-fetoprotein (ng/ml) 3.62 ± 1.79 3.54 ± 2.05 3.52 ± 1.55 4.02 ± 1.84 .09 
Creatinine (mg/dl) 0.89 ± 0.40 0.82 ± 0.23 0.92 ± 0.43 0.94 ± 0.54 .02 
eGFR, mL/min/1.73m2 87.7 ± 22.8 92.1 ± 20.6 85.1 ± 23.4 85.6 ± 23.8 <.01 
eGFR <60 mL/min/1.73m2 58 (13) 13 (8) 33 (15) 12 (16) .04 
History of vascular diseases, n (%) 39 (9) 14 (9) 18 (8) 7 (9) .95 
History of malignancies, n (%) 22 (5) 14 (9) 6 (3) 2 (3) .04 
Aspirin therapy, n (%) 24 (5) 11 (8) 10 (5) 3 (4) .08 
NAFLD fibrosis score 0.28 ± 1.58 -0.22 ± 1.59 0.20 ± 1.44 1.55 ± 1.20 <.01 
FIB-4 2.71 ± 2.05 1.96 ± 1.35 2.45 ± 1.50 4.99 ± 2.86 <.01 
10-y heart/stroke risk score a 12.9 ± 11.1 11.4 ± 10.1 13.9 ± 11.2 13.5 ± 11.6 .12 
Biopsy length (mm) 18.9 ± 5.1 19.1 ± 5.2 19.1 ± 5.4 18 ± 3.8 .21 
Portal tracts (n) 9.7 ± 2.9 10.1 ± 3.6 9.6 ± 2.6 9.1 ± 1.7 .09 
NAS 4.2 ± 1.9 4.4 ± 1.8 4.3 ± 1.8 3.2 ± 1.7 <.01 
NAS distribution, n (%) b     <.01 
   < 3 85 (19) 26 (16) 35 (16) 24 (31)  
    3-4 174 (38) 56 (35) 81 (36) 37 (48)  
    ≥ 5 199 (43) 77 (49) 106 (48) 16 (21)  
Steatosis 1.77 ± 0.87 1.99 ± 0.85 1.77 ± 0.81 1.28 ± 0.88 <.01 
   <33% 181 (40) 42 (26) 86 (39) 53 (69) <.01 
Lobular inflammation 1.34 ± 0.83 1.37 ± 0.85 1.37 ± 0.85 1.16 ± 0.74 .12 
   None or < 2 foci per 200x field 258 (56) 83 (52) 116 (52) 69 (77) <.01 
Ballooning 1.05 ± 0.73 1.05 ± 0.69 1.11 ± 0.74 0.79 ± 0.61 <.01 
   None or few cells 323 (71) 120 (75) 139 (63) 64 (83) <.01 
Country, n (%)     <.01 
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   Spain c 184 (40) 66 (41) 77 (34) 41 (53)  
   Australia d 116 (25) 48 (30) 50 (23) 18 (23)  
   Hong-Kong 82 (18) 35 (22) 45 (20) 2 (3)  
   Cuba 76 (17) 10 (7) 50 (23) 16 (21)  
Abbreviations: CTP, Child-Turcotte-Pugh, BMI, body mass index; MELD, Model for End-Stage Liver Disease; 
ALT, alanine aminotransferase; AST, aspartate aminotransferase; HbA1c, glycated hemoglobin; HOMA-IR, 
Homeostatic Model Assessment of Insulin Resistance; INR, international normalized ratio; HDL, high-density 
lipoprotein; LDL, low-density lipoprotein; eGFR, estimated glomerular filtration rate; NAFLD, nonalcoholic fatty 
liver disease; NAS, NAFLD activity score.  
Quantitative data were expressed as mean ± SD.    
For all laboratory measures and for continuous demographics: One-way ANOVA test with Bonferroni adjustments. 
Proportions: percentage, Mantel-Haenszel Chi-Square test for trend.  
The eGFR was computed by EPI-CKD formula. 
a The 10-year risk of heart disease or stroke using the ASCVD algorithm.31  
b NAS indicates NAFLD activity score. It was defined as the unweighted sum of the scores for steatosis (0-3), 
lobular inflammation (0-3), and ballooning (0-2); thus, ranging from 0 to 8. 
c Patients of two Spanish centers were recruited (Hospital Universitario Virgen del Rocio, Seville, Spain [164 
patients] and Hospital Clinico Universitario de Valladolid, Valladolid, Spain [30 patients]. 
d Patients of two Australian centers were recruited (School of Medicine and Pharmacology, The University of 
Western Australia, Nedlands, Australia [90 patients] and Sydney Medical School, Storr Liver Centre, The 
Westmead Institute for Medical Research, Sidney, Australia [26 patients]. 
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Table 2. Clinical outcomes during the follow-up based on fibrosis stages and CTP classes. 
 
Clinical outcomes 
Overall 
n=458 
N (%) 
Bridging fibrosis 
n=159 
N (%) 
Cirrhosis 
CTP A5  
n=222 
N (%) 
Cirrhosis 
CTP A6 
n=77 
N (%) 
Overall mortality or liver transplant 74 (16) 4 (3) 25 (11) 45 (58) 
  Deaths 37 (50) 4 (100) 15 (60) 18 (40) 
      Liver-related 31 (85) 2 (50) 11 (73) 18 (100) 
      Non-liver-related 6 (15) 2 (50) 4 (27) 0 (0) 
   Liver transplantation 37 (50) 0 (0) 10 (40) 27 (60) 
First occurrence of a major clinical event a 141 (31) 26 (16) 63 (28) 52 (66) 
  Hepatic decompensation 86 (61) 5 (19)  37 (59) 44 (85)  
  HCC 22 (16) 2 (8)  12 (19) 8 (15) 
  Non-hepatic malignant neoplasms 20 (14) 10 (38) 10 (16) 0 (0) 
  Major vascular events 13 (9) 9 (35) 4 (6) 0 (0) 
First event of hepatic decompensation 88 (19) 5 (3) 38 (17) 45 (58) 
  Ascites   62 (70) 2 (40) 27 (71) 33 (73) 
  Variceal hemorrhage 21 (24) 3 (60) 8 (21) 10 (22) 
  Hepatic encephalopathy 5 (6) 0 (0) 3 (8) 2 (5) 
Hepatocellular carcinoma  41 (9) 2 (1) 21 (9) 18 (23) 
Total major vascular events 14 (3) 8 (5) 5 (2) 1 (1) 
  Heart ischemic disease 10 (71) 7 (88) 3 (60) 0 (0) 
  Stroke 4 (29) 1 (12) 2 (40) 1 (100) 
Total non-hepatic malignancies b 30 (7) 13 (8) 10 (5) 7 (9) 
Lost to follow-up 4 (1) 1 (1) 3 (1) 0 (0) 
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Abbreviations: CTP, Child-Turcotte-Pugh; HCC, hepatocellular carcinoma. 
a It includes the occurrence of a first major clinical event during follow-up period. Subsequent events were not 
accounted for. 
b Colorectal cancer, 15; skin cancer, 6 (5 basal cell carcinoma and 1 melanoma); esophageal cancer, 
1; lung cancer, 1; pancreatic cancer, 1; cholangiocarcinoma, 1; uterine cancer, 2; breast cancer, 3. 
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Table 3. Annualized incidence rates of each clinical outcome according to fibrosis stages and CTP classes. 
Variable 
Bridging fibrosis 
n=159 
Cirrhosis and CTP A5 
n=222 
Cirrhosis and CTP A6 
n=77 
No. Rates 95% CI No. Rates 95% CI No. Rates 95% CI 
All deaths or transplantations 4 0.5 0.2-1.2 25 2.1 1.4-3.1 45 11.1 8.3-14.8 
First occurrence of major 
clinical outcomes 
26 3.2 2.2-4.7 63 5.9 4.6-7.6 52 18.3 13.9-24 
First occurrence of hepatic 
decompensation 
5 0.6 0.2-1.4 38 3.3 2.4-4.6 45 15.6 11.7-20.9 
Development of 
hepatocellular carcinoma 
2 0.2 0.02-0.9 21 1.8 1.1-2.7 18 4.7 3.0-7.5 
Total major vascular events a 8 0.9 0.5-1.8 5 0.4 0.2-1.0 1 0.2 0.03-0.6 
Total non-hepatic 
malignancies 
10 1.2 0.6-2.2 10 0.8 0.4-1.5 3 0.7 0.2-1.4 
a Major vascular events included cardiovascular, cerebrovascular, and arterial peripheral diseases.  
Recurrence of clinical events and skin cancers were not computed for analysis purpose.  
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Table 4. Variables found as significant predictors of overall mortality or transplant, hepatic decompensation and 
hepatocellular carcinoma. Results based on multivariable Cox or competing risk regression models.   
Variable 
Overall 
mortality/transplant a  
n=74 
Hepatic decompensation b  
n=88 
Hepatocellular 
carcinoma b 
n=41 
Multivariable Multivariable Multivariable 
HR (95% CI) P sHR (95% CI) P sHR (95% CI) P 
 Model 1 (including severity of fibrosis)c  
Cirrhosis (yes) 5.99 (2.12-16.9) <.01 6.55 (2.53-16.96) <.01 6.52 (1.38-30.8) <.01 
 Model 2 (including CTP score and F3 as reference)d 
CTP score A5 3.83 (1.30-11.23) <.01 4.47 (1.76-12.79) <.01 6.7 (1.4-32.07) <.01 
CTP score A6 21.26 (6.98-64.8) <.01 19.42 (7.03-53.67) <.01 8.15 (1.57-42.09) <.01 
 Model 3 (including steatosis < 33%)e 
Steatosis < 33% (yes) 2.56 (1.35-4.82) <.01 2.64 (1.39-5.03) <.01 2.21 (1.14-3.79) <.01 
 Model 4 (including other potential predictors)f 
Age, y 1.03 (1.01-1.06) .01 - - 1.05 (1.01-1.10) .01 
Gender (male) 1.87 (1.08-2.85) .04 - - 7.28 (3.1-17.1) <.01 
Current smoking (yes) 1.74 (1.03-2.98) .03 - - 2.11 (1.17-5.27) .01 
Type 2 diabetes (yes) 3.33 (1.69-6.54) <.01 2.82 (1.54-5.15) <.01 4.72 (2.13-10.45) <.01 
INR 7.19 (3.09-16.7) <.01 4.34 (1.41-13.33) .01 - - 
Total bilirubin (mg/dl) 1.62 (1.19-2.21) <.01 1.7 (1.4-2.1) <.01 - - 
Platelet (x 109 L) 0.99 (0.98-0.99) .02 0.98 (0.97-0.99) .01 - - 
Albumin (g/dl) 0.56 (0.30-0.91) .05 0.47 (0.26-0.88) .01 - - 
AST/ALT ratio 1.86 (1.12-3.09) .01 1.56 (1.03-2.98) .03 - - 
MELD score 1.10 (1.02-1.18) <.01 - - - - 
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GE varices (yes) 2.19 (1.13-3.71) <.01 1.99 (1.16-3.05) .01 - - 
Abbreviations: CTP, Child-Turcotte-Pugh; CI, confidence interval; sHR, subhazard ratios; MELD, Model for End-
Stage Liver Disease; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GE, gastroesophageal.  
a Multivariable Cox regression models.  
b Multivariable competing risk regression models. 
c Multivariable analyses for model 1 (see supplementary Table 11) were adjusted by center, race/ethnicity, age, 
gender, calendar year of patients’ recruitment, baseline BMI, hypertension, history of previous vascular events or 
malignant neoplasm, anti-diabetic, antihypertensive and hypolipidemic drugs and aspirin. Current smoking and 
diagnosis of type 2 diabetes were included as time-varying covariates.     
d Multivariable analyses for model 2 (see supplementary Table 12) were adjusted by the same variables than model 1.  
e Multivariable analyses for model 3 (see supplementary Table 13) were adjusted by the same variables than model 1 
plus other liver-related tests such as INR, bilirubin, albumin, AST/ALT ratio and platelet count and excluding fibrosis 
severity on liver histology and CTP score.    
f Multivariable analyses for model 4 (see supplementary Table 14) included other variables that were significant at 
univariate analysis (supplementary appendix, Table 4) while adjusting by fibrosis severity at baseline, center, 
race/ethnicity, calendar year of patients’ recruitment, gender, baseline BMI, hypertension, anti-diabetic, 
antihypertensive and hypolipidemic drugs, aspirin, history of previous vascular events or malignant neoplasm and 
steatosis.  
Type 2 diabetes and current smoking were analyzed as time-dependent covariates.  
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FIGURES 
Fig. 1. Adjusted a overall survival without transplant according to fibrosis stage and 
CTP class.  
a Survival curves correspond with adjusted predictions calculated from the Cox 
proportional regression model while adjusting by center and calendar year of patient 
recruitment.  
Fig. 2. Adjusted a cumulative incidences of the first occurrence of major clinical 
outcomes according to fibrosis stage and CTP class. 
(A) Hepatic decompensation. 
(B) Hepatocellular carcinoma. 
(C) Major vascular events 
(D) Non-hepatic malignant neoplasm 
a Cumulative incidence curves corresponds with adjusted predictions calculated by 
competing-risks regression models while adjusting by center and calendar year of patient 
recruitment.  
Fig. 3. Influence of hepatic steatosis on liver-related outcomes in cirrhotic patients. 
(A) Overall survival without transplant by steatosis and CTP score. Cox model adjusted 
probabilities. a 
(B) Hepatic decompensation by steatosis and CTP score. Competing-risks adjusted 
cumulative incidences. b 
(C) HCC development by steatosis and CTP score. Competing-risks adjusted cumulative 
incidences. c 
a HR for CTP-A5 + steatosis < 33% = 3.9 (95% CI: 1.7-9.4), CTP-A6 + steatosis ≥ 33% 
= 10.8 (95% CI: 4.9-23.5) and CTP-A6 + steatosis < 33% = 18 (95% CI: 7-45.5). Cox 
model adjusted P<0.05 for difference among groups.  
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b sHR for CTP-A5 + steatosis < 33% = 4.4 (95% CI: 2.5-9.1), CTP-A6 + steatosis ≥ 
33% = 12.1 (95% CI: 5.9-24.8) and CTP-A6 + steatosis < 33% = 12.8 (95% CI: 5.4-
30.1). No statistically significant difference between CTP-A6 + steatosis ≥ 33% and 
CTP-A6 + steatosis < 33%.  
c sHR for CTP-A5 + steatosis < 33% = 2.4 (95% CI: 1.01-5.5) and CTP-A6 + steatosis 
< 33% = 3.8 (95% CI: 1.6-8.7). No statistically significant difference among CTP-A5 
and A6 with steatosis > 33%.  
Cumulative probability or incidence curves for each outcome indicates adjusted 
predictions calculated by Cox or competing-risks regression models adjusted by center 
and calendar year of patient recruitment.  
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METHODS 
Data collection 
All patients were enrolled and assessed by experienced hepatologists in each 
participating center. The demographic and clinical data included age, gender, race, body 
weight in kg, height, body mass index (BMI), history of comorbidities, including 
hypertension and type 2 diabetes, and concurrent medications, self-reported cigarette 
smoking in the two years preceding enrollment. History of cardiovascular, 
cerebrovascular, and peripheral arterial disease, and previous malignancies was 
recorded. Laboratory parameters, including aminotransferases, GGT, bilirubin, serum 
albumin and creatinine, INR, platelets, fasting glucose and insulin, hemoglobin A1c, 
serum total and HDL cholesterol, triglycerides, LDL cholesterol and alpha-fetoprotein 
were collected.  
Alcohol use information was obtained via patient interview and confirmed by relatives 
at baseline and during follow-up visits. Patients were asked to describe their alcohol 
consumption during a typical week, changes during the last 2 years, as well as changes 
in alcohol consumption during each follow-up visit. Type (wine, beer, and liquor) and 
amount of beverages drunk during a week was considered for computing weekly 
alcohol intake. The amount of each beverage type was summed to obtain a total 
quantity, and an average daily quantity was calculated. A standard drink of wine was 
considered to contain 4 ounces, beer 12 ounces, and liquor 1.5 ounces of ethanol. To 
compute weekly alcohol intake during each clinic visit, the number of drinking episodes 
was multiplied by the number of drinks (in grams of ethanol) consumed on each 
episode. Subjects who reported two or more episodes of alcohol consumption over 140 
g/week (men) and 70 g/week (women) were excluded. Alcohol consumption was 
classified into (1) non-drinkers: lack of alcohol intake or (2) moderate drinkers: between 
1-70 g/week (women) and 1-140 g/week. 
Body weight was measured on calibrated scales by clinical staff.  
Type 2 diabetes was defined as fasting glucose ≥ 126 mg/dL or HbA1c ≥ 6.5 % or use 
of insulin or oral hypoglycemic medication. Fasting blood glucose or HbA1c or any 
newly prescribed antidiabetic medication on follow-up visits were used to detect new-
onset diabetes among those subjects with diabetes at baseline. Hypertension was defined 
as systolic blood pressure >130/85 mmHg or taking antihypertensive medications. 
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Follow-up and events assessment 
A comprehensive protocol including specifications on outcomes assessments was 
distributed and discussed among all participating centers, and 1 or 2 experienced local 
investigators confirmed and certified the occurrence and type of outcome based on 
protocol specifications. Finally, reported outcomes were re-assessed by 2 investigators 
(EVG and LCB) to assurance the quality of reports. 
During the follow-up, patients with elevated AFP levels and/or new lesions suspected or 
detected during US examination were further evaluated with either triphasic 
computerized tomography (CT), contrast-enhanced magnetic resonance (MR) imaging, 
hepatic angiography and/or ultrasound-guided needle liver biopsy. 
Upper digestive endoscopies were performed by each local center following 
recommended guidelines for the management of patients with cirrhosis.1 
Clinical outcomes occurring after liver transplantation were not considered. Each 
clinical event was verified and confirmed by the local investigator after extensive 
review of the patient clinical history, examination findings and investigations. 
Diagnoses of liver- and nonliver-related clinical events such as ascites, variceal 
hemorrhage, hepatic encephalopathy, spontaneous bacterial peritonitis, HCC and 
cardiovascular/cerebrovascular were made according to standardized accepted criteria.1-
8 Diagnoses of non-hepatic cancers were verified using histopathology and/or cytology 
findings.      
Information on body weight, alcohol consumption, smoking status and diabetes status 
were systematically collected in each follow-up visit.  
Histological analysis 
Liver histology was assessed using hematoxylin and eosin (H&E) stains in paraffin-
embedded sections using standardized methods. Fibrosis was assessed using both 
Masson’s trichrome and Sirius Red stains in paraffin-embedded sections using 
established methodology. The grade of individual pathological features of NAFLD was 
scored on H&E-stained tissue.  
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In order to provide reliable estimation of grading and staging, only those biopsy 
specimens with a length greater than 10 mm and containing more than six portal tracts 
were included for analysis.  
Inter-rater agreements between local histopathological (6 raters) and central readings (1 
rater*) in 48 randomly selected patients (23 patients with bridging fibrosis and 25 with 
cirrhosis).  
 
Histological 
variables 
Inter-rater agreements using Kappa statistics 
HK 
N=10 
Australia-
WH 
N=10 
Australia-
SCGH 
N=9 
Spain-
VRUH 
N=7 
Spain-
VUH 
N=6 
Cuba-
NIG 
N=6 
Fibrosis 1.0 0.80 0.89 1.0 0.84 0.85 
Steatosis 0.85 0.81 0.83 0.72 0.71 0.75 
Lobular 
inflammation 
0.63 0.44 0.53 0.58 0.48 0.45 
Ballooning 0.75 0.54 0.53 0.59 0.55 0.57 
* The pathologist (A.C) participating in central readings was not involved in initial 
readings. He was unaware of initial pathological reports and study information. 
Abbreviations: HK, Hong Kong; WH, Westmead Hospital; SCGH, Sir Charles 
Gairdner Hospital; VRUH, Virgen del Rocio University Hospital; VUH, Valladolid 
University Hospital; NIG, National Institute of Gastroenterology.  
Statistical analysis 
Non-liver deaths were considered as competing events for liver-related mortality and 
transplant, hepatic decompensation and HCC; non-vascular deaths and transplant for 
vascular events; and non-cancer deaths, HCC-deaths or transplant for non-hepatic 
malignant neoplasms.  
The Fine and Gray model is based on the hazard of the subdistribution and provides a 
simple relationship between covariates and cumulative incidence. As in any other 
regression analysis, modelling cumulative incidence functions for competing risks can 
be easily used for identifying potential prognostic factors for a particular outcome in the 
presence of competing risks events, or to assess a prognostic factor of interest after 
adjusting for other potential risk factors in the model.  
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As an example, the standard Cox model, like to the standard Kaplan-Meier estimator, 
may introduce a bias in the estimates of absolute risk because it fails to treat subjects 
who die of non-liver related causes as ineligible for development of liver-related deaths 
or other liver-related events. Standard methods treat inadequately competing events as if 
they were censored. In competing risk analysis, subhazard ratios (sHR) can be 
interpreted similarly to hazard ratios (HR) in Cox regression models. 
Covariates were selected for analysis according to their biologically plausible potential 
to act as confounders or predictors for each outcome. The potential predictors at 
baseline were as follows: age, gender, race/ethnicity, fibrosis stages (bridging fibrosis 
vs. cirrhosis) and CTP score classes (A5 and A6), total bilirubin, albumin, platelets, 
total cholesterol, INR, AST/ALT ratio, diabetes mellitus, individual histological lesions 
(lobular inflammation, steatosis and ballooning), gastroesophageal varices at baseline 
and MELD score. Smoking status, alcohol consumption and diagnosis of type 2 diabetes 
were considered as time-dependent covariates.     
The diagnosis of new-onset diabetes over time among non-diabetic patients was 
systematically collected during each visit. The first follow-up contact at which there 
was new diabetes diagnosis was utilized to define conversion to diabetes during follow-
up. In all analyses including incident diabetes, a time-varying covariate was generated 
by considering change in diabetes status over time. In other words, we considered 
patients in the non-diabetes group until they developed diabetes. Similarly, among non-
smoking and non-drinkers patients, the first follow-up contact at which there was a new 
episode of smoking or alcohol intake was utilized to define conversion to smoking or 
drinkers during follow-up. Among smoking and drinker patients, the first follow-up 
contact at which patients became a non-drinker and non-smoking was utilized to define 
conversion to non-smoking or non-drinker during follow-up. In all analyses including 
smoking and alcohol intake, a time-varying covariate was generated by considering 
change in status of smoking or alcohol consumption over time. 
All cumulative outcomes rates including transplant-free survival, and nonliver-related 
clinical events were adjusted by centers and calendar year of patients’ recruitment.  
Patients with history of severe vascular diseases or malignant neoplasm and reduced life 
expectancy were excluded. In patients with pre-existing vascular disease, a new episode 
of vascular disease including myocardial infarction, coronary artery disease, stable and 
unstable angina, impairment of heart failure, cardiac arrest, stroke, carotid or aortic 
artery disease, and transient ischemic attacks was considered as a new event and it was 
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accounted for analysis. Follow-up time for vascular event start at enrollment and 
continued until the first diagnosis of a vascular event. Subjects with cancers and 
palliative care or oncology treatment at enrollment (including surgery, chemotherapy 
or radiotherapy) were excluded. We assumed a second primary malignancy as a new 
event, and relapse of the same malignancy was not accounted for analysis. Pre-existing 
history of vascular events or malignancy was included as a covariate in all multivariable 
analyses. 
When the prognostic models (CTP and MELD scores) and their individual components 
were significant at univariate analysis, multivariable models included separately the 
single components and the scores to avoid redundancy. Similarly, fibrosis severity and 
steatosis grades were evaluated in independent models. The collinearity between factors 
included in the multivariable analyses was checked by using VIF (variance inflation 
factor) and tolerance (1/VIF) values. Variables with very high VIF values indicating 
possible redundancy entered into different multivariable models.  
 All multivariable analyses were also adjusted by center, race/ethnicity, calendar year of 
patients’ recruitment, hypertension, anti-diabetic, antihypertensive and hypolipidemic 
drugs, aspirin, and history of previous vascular events or malignant neoplasm.  
Variables that were significant (p<0.15) in univariate analysis and those known as 
weighted prognostic indicators were included in multivariable analysis. Backward 
stepwise selection method was implemented for variable selection in Cox proportional 
hazard and competing risks regression models.  
All adjusted Cox and competing risk regression models were performed on the dataset 
containing imputed values. A graphical assessment of proportional assumptions was 
performed using log-log survival curves. In addition, deviations from the assumption of 
proportionality were tested for each covariate and also globally, using Schoenfeld 
residuals. The assumptions of proportionality were met both globally (the overall 
models) and individually for each predictor variable. 
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Proportion of missing data for potential predictors 
Variables Proportion of missing data 
Clinical  
Smoking status 6% 
Body weight  4% 
Alcohol consumption 0% 
Metabolic determinations  
Cholesterol 4% 
Triglycerides 4% 
HDL cholesterol 4% 
LDL cholesterol 4% 
HbA1c 6% 
Fasting insulin/HOMA-IR 8% 
Liver tests  
ALT 0% 
AST 0% 
Albumin 0% 
INR 0% 
Bilirubin 0% 
Platelets 0% 
GGT 1% 
Other tests 0% 
MELD 0% 
Creatinine/eGFR 0% 
Upper GI endoscopy* 0% 
* All cirrhotic patients underwent varices screening at baseline.  
 
Proportion of missing data during the follow-up for time-dependent predictors 
Smoking status 2% 
Alcohol consumption 0% 
 
We applied a method of multiple imputations by chained equation (MICE) in which missing 
data are imputed or replaced with a set of plausible values.9-11 MICE is an interactive 
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imputation method that imputes multiple variables by using chained equations, a sequence of 
univariate imputations methods with fully conditional specifications of predictions equations. 
We included transplant-free survival as outcome and baseline or time-varying predictors 
including alcohol consumption, smoking, severity of fibrosis and liver disease, diabetes, age, 
gender, concurrent medications and all potential confounders in the imputation procedure. We 
did 20 imputations for each missing information.  
 
RESULTS 
The mean follow-up in years based on race/ethnicity was as follow: Non-Hispanic 
White, 4.2; Hispanic White, 6.2; Asian, 4.9 and Black, 8.2 (One-way ANOVA P=0.22). 
The mean follow-up was not different among patients with bridging fibrosis and 
cirrhosis with CP class A5 and A6 (see supplementary Figure 1). 
As shown in supplementary Table 2, some key baseline characteristics were 
significantly different among countries. For instance, Hong Kong patients showed less 
severity of liver disease, as determined by some liver tests such as INR, albumin, total 
bilirubin and platelet, in comparison with the remaining countries, and this finding may 
explain the lower proportion of patients with CTP A6 among Hong Kong subjects. 
Since many comorbidities (e.g., diabetes, arterial hypertension) and liver- and non-liver-
related blood tests (e.g., cholesterol, albumin, bilirubin, INR, etc.) may be influenced by 
the severity of liver disease, supplementary Table 2 also shows adjusted analysis by 
fibrosis and CTP score. Interestingly, only BMI and waist circumference were 
statistically different among all countries after adjustments by severity of liver disease  
which suggest the differences in baseline characteristics were greatly influenced by the 
proportion of patients with cirrhosis and CTP A6 that were enrolled in each country (see 
also Table 1). Based on the previous analysis and considering that severity of fibrosis 
and CTP (A5 vs. A6) classes are related to study outcomes, all statistical analysis 
included adjustments by both variables.  
Fifty-eight (13%) patients had an estimated glomerular filtration rate of <60 
mL/min/1.73m2 of whom 45 (78%) had cirrhosis. Five patients underwent dialysis or 
renal transplant during follow-up due to marked impairment of renal function. 
Survival and clinical outcomes over time 
A total of 74 deaths (37, 50%) or liver transplants (37, 50%) occurred; 141 (31%) 
patients developed at least a first major clinical event (86 [61%] hepatic 
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decompensations, 22 [16%] HCCs, 13 [9%] major vascular events and 20 [14%] non-
hepatic malignancies) and 4 (1%) subjects were lost to follow-up. 
Supplementary Figure 2 illustrates transplant-free survival in overall cohort after 
adjustments by center, calendar year of recruitment and baseline fibrosis. 
Transplant-free survival was 88% (95% CI: 84-96), 75% (95% CI: 69-93) and 57% 
(95% CI: 49-64) at 5, 7 and 10 years follow up, respectively in cirrhotic patients. The 
supplementary Figure 6 displays survival rates among patients with bridging fibrosis 
and compensated cirrhosis, including both CTP A5 and A6 in the same group. 
Race/ethnicity as predictors of outcomes  
Although Asian patients had better rates of survival and liver-related outcomes than 
remaining ethnic subgroups, these differences disappeared after adjustments by Child-
Pugh score or other parameters related to severity of liver disease (INR, bilirubin, 
albumin or platelets). Only 2% of Asian patients had a CP score of 6 as compared to 
16% and 22% of Hispanic- and non-Hispanic White subgroups (see Table 1 and 
supplementary Figures 3 A-B). There were too few Blacks to perform meaningful 
analyses of individual outcomes by this ethnic subgroup. 
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TABLES 
Table 1. Distribution of biochemical components in patients with 
CTP class A6  
Biochemical components 
CTP score  
Cut-off 
values 
CPT-A6 
n=77 
N (%) 
Albumin (g/dl) >3.5 
 
47 (61) 
 2.8-3.5 30 (39) 
INR          <1.7 71 (92) 
 1.7-2.2 6 (8) 
Bilirubin (mg/dl)  < 2 
 
61 (79) 
 2-3 16 (21) 
Patients with albumin <3.0 g/dL, total bilirubin > 3.0 mg/dL and 
INR >2 were excluded in our study. 
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Table 2. Key baseline characteristics by countries.  
Variable 
Spain 
n=184 
Australia 
n=116 
Hong Kong  
n=82 
Cuba 
n=76 
P 
value 
c 
Ajd. P 
value d 
Clinical       
Age (y) 54.4 ± 9.9 56.4 ± 12.4 56.9 ± 10.4 56.1 ± 10.6 0.08 0.19 
Male, n (%) 97 (50) 53 (46) 43 (52) 25 (38) 0.44 0.37 
Current smoking, n (%) 47 (24) 15 (13) 7 (9) 9 (12) 0.23 0.11 
Alcohol consumption, n (%)       
Moderate drinkers 25 (13) 18 (16) 15 (18) 8 (12) 0.76 0.62 
History of hypertension, n (%) 119 (61) 62 (53) 61 (74) 39 (59) 0.02 0.09 
Type 2 diabetes, n (%) 117 (60) 80 (69) 66 (80) 42 (63) 0.08 0.20 
BMI (kg/m2)    34.7 ± 9.2 36.6 ± 8.9 28.5 ± 4.9 28.8 ± 4.4 <0.01 <0.01 
Waist (cm) 109.8 ± 12.9 114.2 ± 16.7 97 ± 14.1 96.3 ± 13.1 <0.01 <0.01 
History of vascular diseases, n (%) 14 (8) 14 (12) 6 (7) 5 (6) 0.15 0.17 
10-y heart/stroke risk score a 12.3 ± 11.6 12.8 ± 12.9 13.9 ± 12.1 14.1 ± 12.7 0.28 0.23 
Biochemical       
MELD score 7.8 ± 2.4 7.8 ± 2.9 7.2 ± 1.8 8.1 ± 2.8 0.05 0.15 
ALT (U/L) 64.3 ± 43.4 64.8 ± 51.7 66.2 ± 36.3 68.3 ± 41.8 0.88 0.96 
AST (U/L) 61.6 ± 37.5 54.5 ± 37.5 50.4 ± 27.9 75.9 ± 66.2 0.42 0.33 
AST/ALT ratio 1.09 ± 0.52 0.95 ± 0.36 0.86 ± 0.35 1.25 ± 0.45 0.04 0.14 
Total bilirubin (mg/dl) 0.78 ± 0.45 0.84 ± 0.74 0.65 ± 0.18 1.19 ± 0.65 <0.01 0.17 
Albumin (g/dl) 4.07 ± 0.35 4.09 ± 0.42 4.44 ± 0.29 4.10 ± 0.49 <0.01 0.15 
INR 1.09 ± 0.31 1.08 ± 0.20 1.02 ± 0.05 1.15 ± 0.36 <0.01 0.13 
Platelets (x 109/L)  172 ± 56 196 ± 83 210 ± 72 167 ± 61 0.01 0.09 
HbA1c (%) 7.32 ± 1.95 6.76 ± 1.82 7.15 ± 1.5 6 ± 1.92 <0.01 0.23 
HOMA-IR 9.5 ± 6.9 8.7 ± 6.2 6.3 ± 5.4 6.1 ± 5.1 <0.01 0.08 
Cholesterol (mg/dl) 198.4 ± 50.8 165.4 ± 48.2 170.3 ± 40.9 175.3 ± 61.6 <0.01 0.14 
HDL cholesterol (mg/dl) 44.6 ± 10.8 43.8 ± 12.4 49.6 ± 14.4 40.2 ± 4.2 0.03 0.25 
LDL cholesterol (mg/dl) 117.6 ± 44.9 90.4 ± 36.9 94.3 ± 38.4 105.4 ± 53 0.13 0.31 
Triglycerides (mg/dl)  169.7 ± 87 152.1 ± 78.7 171 ± 119.7 183.3 ± 84.6 0.08 0.29 
α-fetoprotein (ng/ml) 3.79 ± 1.92 3.46 ± 1.66 3.37 ± 1.76 3.71 ± 1.67 0.44 0.37 
eGFR <60 mL/min/1.73m2 18 (9) 19 (16) 11 (13) 10 (15) 0.16 0.52 
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Liver histology       
Biopsy length (mm) 19.2 ± 4.1 17.8 ± 5.5 19.4 ± 6.3 19.9 ± 4.7 0.15 0.16 
Portal tracts (n) 10.9 ± 2.8 8.9 ± 2.5 8.3 ± 3.2 9.6 ± 2.2 0.08 0.06 
NAS b 4.3 ± 1.6 4.2 ± 1.9 4.1 ± 1.2 4.1 ± 1.9 0.05 0.11 
Steatosis 1.85 ± 0.80 1.60 ± 0.99 1.86 ± 0.74 1.68 ± 0.93 0.04 0.10 
Lobular inflammation 1.41 ± 0.68 1.29 ± 0.61 1.37 ± 0.61 1.28 ± 0.80 0.01 0.08 
Ballooning 1.18 ± 0.62 1.04 ± 0.49 1 ± 0.56 0.96 ± 0.71 <0.01 0.13 
Abbreviations: MELD, Model for End-Stage Liver Disease; ALT, alanine aminotransferase; AST, 
aspartate aminotransferase; HbA1c, glycated hemoglobin; HOMA-IR, Homeostatic Model Assessment of 
Insulin Resistance; HDL, high-density lipoprotein; LDL, low-density lipoprotein; INR, international 
normalized ratio; eGFR, estimated glomerular filtration rate; NAS, NAFLD activity score.  
Quantitative data were expressed as mean ± SD.  
The eGFR was computed by EPI-CKD formula. 
Vascular diseases include cardiovascular, cerebrovascular and peripheral vascular diseases. 
a The 10-year risk of heart disease or stroke using the ASCVD algorithm published in 2013 ACC/AHA Guideline 
on the Assessment of Cardiovascular Risk.12  
b NAS indicates NAFLD activity score. It was defined as the unweighted sum of the scores for steatosis (0-3), 
lobular inflammation (0-3), and ballooning (0-2); thus, ranging from 0 to 8. 
c For continuous variables, one-way analysis of covariance (ANCOVA) with Bonferroni adjustments for multiple 
comparisons (P<0.01). For qualitative variables, Mantel-Haenszel chi-square test for trend. 
d Adjusted analysis by fibrosis severity and CTP score at baseline.   
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Table 3. Clinical outcomes during the follow-up. 
 
Clinical outcomes 
Overall 
n=458 
N  
Overall mortality and liver transplant 74  
Deaths 37  
 Liver-related 31  
    Hepatorenal syndrome 7 
    HCC 6 
    Spontaneous bacterial peritonitis 3 
    Hepatic encephalopathy 4 
    Variceal bleeding 2 
    Systemic sepsis 4 
    Acute on chronic liver failure 2 
    Liver failure 2 
    Cholangiocarcinoma 1 
 Non liver-related 6  
   Cardiac arrest 1 
    Lung cancer 1 
    Aortic abdominal aneurysm rupture 1 
    Myocardial infarction  1 
    Colorectal cancer 2 
Liver transplantation 37  
   Hepatic decompensation 26 
   Hepatocellular carcinoma 6 
   End-stage kidney disease a 5 
First events of hepatic decompensation 90  
  Ascites   63  
  Variceal hemorrhage 22  
   Hepatic encephalopathy 5 
Hepatocellular carcinoma  41 
Major vascular events 14 
   Heart ischemic disease 10 
14 
 
   Stroke (ischemic) 4 
Non-hepatic malignant neoplasm 30 
Colorectal cancer 15 
Skin cancer 6 
Breast cancer 3 
Uterine cancer 2 
Esophageal cancer 1 
Lung cancer 1 
Pancreatic cancer 1 
Cholangiocarcinoma 1 
a Five patients underwent double kidney-liver transplantation. 
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Table 4. Variables found as significant predictors of overall mortality or transplant, hepatic decompensation and 
hepatocellular carcinoma. Results based on univariate Cox or competing-risks regression models.    
Variable 
Overall mortality/liver 
transplant a 
n=74 
Hepatic decompensation b 
n=88 
Hepatocellular 
carcinoma b 
n=41 
Univariate Univariate Univariate 
HR P sHR P sHR P 
Cirrhosis (yes) 9.12 <0.01 10.43 <0.01 9.67 <0.01 
Race/ethnicity       
  Asian Ref - Ref - Ref - 
  Non-Hispanic White 3.72 0.02 3.98 <0.01 10.06 0.03 
  Hispanic White 3.23 0.02 6.05 <0.01 5.63 0.06 
Age, y 1.03 0.02 0.99 0.43 1.04 0.02 
Gender (male) 1.27 0.30 0.93 0.75 6.11 <0.01 
Varices (yes) 2.37 <0.01 3.22 <0.01 1.77 0.05 
Current smoking (yes) c 1.6 0.04 2.2 <0.01 2.1 0.01 
BMI (kg/m2) 0.98 0.29 0.97 0.20 0.99 0.73 
Hypertension (yes) 0.69 0.12 0.86 0.49 1.47 0.25 
Type 2 diabetes (yes) c 2.14 <0.01 1.89 0.01 2.91 0.01 
Cholesterol (mg/dl) 0.99 <0.01 0.99 0.05 1.01 0.61 
Statin therapy (yes) 0.74 0.27 0.68 0.10 0.61 0.20 
INR 10.33 <0.01 7.24 <0.01 2.54 0.02 
Albumin (g/dl) 0.32 <0.01 0.26 <0.01 0.44 <0.01 
Total bilirubin (mg/dl) 1.76 <0.01 1.41 <0.01 1.52 <0.01 
AST/ALT 2.89 <0.01 2.69 <0.01 1.27 0.29 
Platelets (x 109/L) 0.98 <0.01 0.98 <0.01 0.99 <0.01 
MELD 1.14 <0.01 1.09 <0.01 1.06 0.22 
CTP score       
   F3 Ref - Ref  - Ref - 
   A5 4.22 <0.01 5.62 <0.01 7.28 <0.01 
   A6 25.12 <0.01 30.43 <0.01 15.47 <0.01 
Steatosis < 33% 4.46 <0.01 4.7 <0.01 3.26 <0.01 
16 
 
Abbreviations: CTP, Child-Turcotte-Pugh; sHR, subhazard ratios; BMI, body mass index; MELD, 
Model for End-Stage Liver Disease; INR, international normalized ratio; ALT, alanine 
aminotransferase; AST, aspartate aminotransferase.  
The CTP and MELD scores are measures of the severity of liver disease. 
a Univariate Cox regression models.  
b Univariate competing risk regression models. 
c Included as a time-dependent covariate.  
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Table 5. Influence of alcohol consumption on clinical outcomes. Cox or competing-risks regression models included alcohol consumption as a time-
varying covariate. 
 
Bridging fibrosis 
n=159 
 
P  
Value a 
Cirrhosis 
n=299 
 
P  
Value a 
Cirrhosis 
N=299 
 Moderate 
 consumption 
N (%) 
Moderate 
consumption 
N (%) 
Adjusted HR or sHR (95% 
CI) for moderate 
consumption 
P 
value b 
Death or transplant No Yes 0.48 No Yes <0.01 2.3 (1.32-4.02) <0.01 
No 140 (97) 15 (100)  209 (81) 20 (20)    
Yes 4 (3) 0 (0)  50 (19) 20 (50)    
HCC development    0.15   <0.01 3.22 (1.64-6.32) <0.01 
No 143 (99) 14 (93)  233 (90) 27 (67)    
Yes 1 (1) 1 (7)  26 (10) 13 (33)    
Hepatic decompensation   0.43   <0.01 1.65 (1.01-2.61) 0.04 
No 142 (91) 15 (100)  212 (72) 21 (52)    
Yes 2 (1) 0 (0)  47 (18) 19 (48)    
Vascular events   0.31   0.56 - - 
No 136 (94) 15 (100)  253 (98) 40 (100)    
Yes 8 (6) 0 (0)  6 (2) 0 (0)  - - 
Non-hepatic malignancies   0.62   0.77   
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No 135 (94) 14 (97)  247 (95) 39 (97)  - - 
Yes 9 (6) 1 (3)  12 (5) 1 (3)  - - 
a Unadjusted P values.   
b P values after adjustments by those variables that were significant at univariate analysis (supplementary appendix, Table 4) and centers, 
race/ethnicity, calendar year of patients’ recruitment, baseline BMI, diabetes, hypertension, anti-diabetic, antihypertensive and hypolipidemic drugs, 
aspirin, and history of previous vascular events or malignant neoplasm. 
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Table 6. Influence of individual histological lesions on overall mortality or transplant and hepatic outcomes. Results based on Cox or 
competing-risks regression models.   
Histological lesion 
Overall mortality/OLT a  
n=74 
 
Hepatic decompensation b 
n=88 
 
Hepatocellular carcinoma b 
n=41 
 
Unadjusted Adjusted c Unadjusted Adjusted c Unadjusted Adjusted d 
 HR P HR P sHR P sHR P sHR P sHR P 
Steatosis           
   < 33% 2.67 <.01 2.50 <.01 2.97 <.01 2.91 <.01 3.53 .01 3.52 .01 
Ballooning           
   None or few cells 1.74 .09 1.68 .11 1.11 .41 1.06 .82 1.14 .72 1.11 .78 
Lobular inflammation          
  None or < 2 foci per 200x field 1.25 .23 1.20 .33 1.09 .61 1.05 .77 1.21 .46 1.29 .30 
Cox a and competing-risks b regression models.    
c Adjusted analyses include centers and calendar year of patients’ recruitment, age, sex, race/ethnicity, CTP classes, diabetes, 
alcohol consumption and baseline BMI.   
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Table 7. Variables found predictors of vascular events. Results based on 
multivariable competing-risks regression models.    
Variable 
Major vascular events (n=14) 
Multivariable 
sHR 95% CI P 
Cirrhosis (yes) a 0.25 0.08-0.71 <0.01 
Age, y 1.05 1.01-1.13 0.04 
BMI (kg/m2) 1.07 1.02-1.17 0.03 
Type 2 diabetes (yes) b 2.15 1.14-7.96 0.02 
LDL cholesterol (mg/dl) 1.06 1.02-1.15 0.02 
a No difference was detected between CTP A5 and A6. 
b Included as a time-dependent covariate.   
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Table 8. Baseline features based on severity of steatosis.    
Variable 
Severity of steatosis 
Steatosis < 33% 
n=181 
Steatosis ≥ 33% 
n=277 
P a 
Age, y 57.8 ± 11.5 54.7 ± 10.9 <.01 
Male (yes), n (%) 78 (43) 140 (51) .12 
BMI (kg/m2) 31.6 ± 7.4 34.2 ± 9.1 <.01 
Type 2 diabetes (yes), n (%) 127 (70) 178 (64) .19 
HbA1c (%) 6.97 ± 1.99 6.95 ± 1.82 0.84 
LDL cholesterol (mg/dl) 98.7 ± 44.3 108.7 ± 44.6 .01 
Triglycerides (mg/dl) 152.3 ± 74.5 177.3 ± 88.3 .01 
Albumin (mg/dl) 4.06 ± 0.44  4.22 ± 0.37 <.01 
INR 1.10 ± 0.17 1.05 ± 0.19 <.01 
AST/ALT ratio 1.15 ± 0.47 0.96 ± 0.44 <.01 
Platelets (x 109/L) 162 ± 69 198 ± 65 <.01 
Total bilirubin (mg/dl) 1.02 ± 0.4 0.72 ± 0.28 <.01 
a Wilcoxon signed-rank test for continuous variables and Chi square test for 
categorical variables.   
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Table 9. Outcomes development based on gender. Adjusted P values based on Cox or 
competing-risk regression models.   
Variable 
Gender 
Male 
n=218 
Female 
n=240 
P a 
Mortality or transplant 40 (18%) 34 (14%) 0.04 
Liver-related decompensation 39 (18%) 49 (20%) 0.52 
HCC 34 (16%) 7 (3%) <0.01 
Vascular events 7 (3%) 7 (3%) 0.78 
Non-hepatic malignancies 9 (4%) 14 (6%) 0.41 
a Adjusted Cox-model or Fine and Gray P values by centers, race/ethnicity, age, calendar 
year of patients’ recruitment, smoking status, alcohol intake, baseline BMI, hypertension, 
anti-diabetic, antihypertensive and hypolipidemic drugs, aspirin, and history of previous 
vascular events or malignant neoplasm.    
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Table 10. Outcomes development considering type 2 diabetes diagnosis as a time varying 
covariate. Adjusted P values based on Cox or competing-risk regression models.   
Variable 
Diagnosis of type 2 diabetes  
No 
n=132 
Yes 
n=326 
P a 
Overall mortality or transplant 13 (10%) 61 (19%) <0.01 
Liver-related decompensation 19 (14%) 69 (21%) <0.01 
HCC 3 (2%) 38 (12%) <0.01 
Vascular events 1 (1%) 13 (4%) 0.01 
Non-hepatic malignancies 7 (5%) 16 (5%) 0.87 
a Adjusted P values by center, race/ethnicity, age, gender, calendar year of patients’ 
recruitment, smoking status, alcohol intake, baseline BMI, hypertension, anti-diabetic, 
antihypertensive and hypolipidemic drugs, aspirin, and history of previous vascular events 
or malignant neoplasm.    
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Table 11. Association between severity of fibrosis (model 1 in Table 4 of main manuscript) and overall mortality or transplant, 
hepatic decompensation and hepatocellular carcinoma. Cox or competing risk regression multivariable analyses including other 
potential confounding or predictive factors.     
Variable 
Overall mortality/liver 
transplant a 
n=74 
Hepatic decompensation b 
n=88 
Hepatocellular carcinoma 
b 
n=41 
Multivariable Multivariable Multivariable 
HR (95% CI) P sHR (95% CI) P sHR (95% CI) P 
Cirrhosis (yes) 5.99 (2.12-16.9) <.01 6.55 (2.53-16.96) <.01 6.52 (1.38-30.8) <.01 
Race/ethnicity       
  Asian Ref - Ref - Ref - 
  Non-Hispanic White 2.65 .13 2.23 .29 3.11 .08 
  Hispanic White 2.84 .11 2.53 .17 4.22 .10 
Age, y 1.03 (1.01-1.06) .01 0.98 .22 1.04 (1.01-1.08) .03 
Gender (male)   1.71 (1.0-2.67) .05 1.11 .27 8.36 (2.75-24.4) <.01 
Current smoking (yes) c 1.69 (1.02-2.87) .04 1.22 .40 3.18 (1.35-7.52) <.01 
Type 2 diabetes (yes) c 2.99 (1.55-5.88) <.01 2.44 (1.33-4.99) <.01 5.92 (1.86-18.8) <.01 
BMI (kg/m2) 0.97 .17 0.97 .27 0.98 .91 
Hypertension (yes) 0.82 .56 0.85 .66 0.68 .42 
History of vascular events (yes) 0.66 .32 0.92 .86 0.88 .85 
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History of malignant neoplasm (yes) 1.44 .54 0.88 .87 0.92 .56 
Statin therapy (yes) 1.19 .58 0.73 .25 0.66 .43 
Glucose-lowering medications (yes) 0.59 .15 0.56 .11 0.78 .51 
Anti-hypertensive medications (yes) 0.66 .29 1.36 .40 0.73 .52 
Aspirin (yes) 0.57 .24 0.78 .69 0.52 .38 
Abbreviations: HR, hazard ratio; sHR, subhazard ratios; BMI, body mass index.  
All multivariable analyses were adjusted by centers and calendar year of patients’ recruitment. 
a Cox regression models.  
b Competing risk regression models. 
c Included as time-dependent covariate.  
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Table 12. Association between CTP score (model 2 in Table 4 of main manuscript) and overall mortality or transplant, hepatic 
decompensation and hepatocellular carcinoma. Cox or competing risk regression multivariable analyses including other potential 
confounding or predictive factors.     
Variable 
Overall mortality/liver 
transplant a 
n=74 
Hepatic decompensation b 
n=88 
Hepatocellular carcinoma b 
n=41 
Multivariable Multivariable Multivariable 
HR (95% CI) P sHR (95% CI) P sHR (95% CI) P 
Bridging fibrosis Ref  Ref  Ref  
CTP A5 3.83 (1.30-11.23) <.01 4.47 (1.76-12.79) <.01 6.7 (1.4-32.07) <.01 
CTP A6 21.26 (6.98-64.8) <.01 19.42 (7.03-53.67) <.01 8.15 (1.57-42.09) <.01 
Race/ethnicity       
  Asian Ref - Ref - Ref - 
  Non-Hispanic White 1.68 .41 1.26 .45 2.85 .35 
  Hispanic White 2.28 .14 2.7 .14 3.77 .18 
Age, y 1.04 (1.01-1.07) .01 0.98 .19 1.06 (1.01-1.11) .01 
 Gender (male) 1.99 (1.01-3.08) .03 0.86 .53 7.31 (2.48-21.5) <.01 
Current smoking (yes) c 1.75 (1.01-2.91) .04 1.34 .19 2.42 (1.10-5.33) .02 
Type 2 diabetes (yes) c 2.78 (1.39-5.25) <.01 2.44 (1.33-4.99) <.01 5.92 (1.86-18.8) <.01 
BMI (kg/m2) 0.99 .60 0.99 .96 0.99 .93 
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Hypertension (yes) 0.70 .31 0.89 .73 1.02 .55 
History of vascular events (yes) 0.54 .28 0.72 .59 0.58 .28 
History of malignant neoplasm (yes) 1.61 .49 1.16 .85 1.05 .37 
Statin therapy (yes) 1.57 .15 0.88 .63 0.70 .44 
Glucose-lowering medications (yes) 0.48 .11 0.61 .13 0.61 .39 
Anti-hypertensive medications (yes) 0.66 .26 1.37 .33 0.60 .39 
Aspirin (yes) 0.61 .28 0.81 .73 0.68 .45 
Abbreviations: HR, hazard ratio; sHR, subhazard ratios; CTP, Child-Turcotte-Pugh; BMI, body mass index.  
All multivariable analyses were adjusted by centers and calendar year of patients’ recruitment. 
a Cox regression models.  
b Competing risk regression models. 
c Included as time-dependent covariate. 
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Table 13. Association between steatosis < 33% (model 3 in Table 4 of main manuscript) and overall mortality or transplant, hepatic 
decompensation and hepatocellular carcinoma. Cox or competing risk regression multivariable analyses including other potential 
confounding or predictive factors.     
Variable 
Overall mortality/liver 
transplant a 
n=74 
Hepatic decompensation b 
n=88 
Hepatocellular carcinoma b 
n=41 
Multivariable Multivariable Multivariable 
HR (95% CI) P sHR (95% CI) P sHR (95% CI) P 
Steatosis < 33% 2.56 (1.35-4.82) <.01 2.64 (1.39-5.03) <.01 2.21 (1.14-3.79) <.01 
Race/ethnicity       
  Asian Ref - Ref - Ref - 
  Non-Hispanic White 1.71 .39 2.30 .25 2.64 .38 
  Hispanic White 2.13 .16 2.76 .12 3.35 .20 
Age, y 1.04 (1.01-1.06) .02 0.98 .11 1.05 (1.01-1.10) .02 
Gender (male) 1.87 (1.01-2.87) .04 0.77 .33 8.73 (3.06-24.9) <.01 
Current smoking (yes) c 1.80 (1.02-2.95) .04 1.34 .19 2.71 (1.12-6.56) .02 
Type 2 diabetes (yes) c 2.84 (1.41-5.44) <.01 3.19 (1.37-7.44) <.01 8.59 (3.02-24.4) <.01 
BMI (kg/m2) 0.99 .92 0.98 .44 0.98 .64 
Hypertension (yes) 0.69 .30 0.73 .34 1.12 .79 
History of vascular events (yes) 0.66 .33 0.69 .48 0.65 .37 
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History of malignant neoplasm (yes) 1.48 .55 1.08 .87 1.02 .41 
Statin therapy (yes) 1.32 .39 0.69 .22 0.76 .60 
Glucose-lowering medications (yes) 0.56 .13 0.77 .47 0.74 .45 
Anti-hypertensive medications  (yes) 0.63 .22 1.33 .37 0.66 .44 
Aspirin (yes) 0.64 .31 0.77 .69 0.72 .51 
INR 8.21 (3.33-17.9) <.01 11.5 (5.66-28.5) <.01 1.67 .42 
Albumin (g/dl) 0.47 (0.26-0.85) .01 0.31 (0.16-0.59) <.01 0.73 .39 
Total bilirubin (mg/dl) 1.93 (1.43-2.61) <.01 1.44 (1.17-1.77) <.01 1.58 .06 
AST/ALT 2.85 (1.50-5.4) <.01 2.38 (1.59-3.58) <.01 1.20 .58 
Platelets (x 109/L) 0.98 (0.98-0.99) <.01 0.98 (0.98-0.99) <.01 0.99 .33 
Abbreviations: sHR, subhazard ratios; BMI, body mass index; ALT, alanine aminotransferase; AST, aspartate aminotransferase; INR, 
international normalized ratio.  
All multivariable analyses were adjusted by centers and calendar year of patients’ recruitment. 
a Cox regression models.  
b Competing risk regression models. 
c Included as time-dependent covariate. 
Since all liver-related tests may reflect severity of liver disease and important collinearity (high VIF) was found between them, each 
variable (INR, albumin, total bilirubin, platelets count and AST/ALT ratio) was evaluated on independent models.     
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Table 14. Association between other potential predictors (model 4 in Table 4 of main manuscript) and overall mortality or 
transplant, hepatic decompensation and hepatocellular carcinoma. Cox or competing risk regression multivariable analyses.      
Variable 
Overall mortality/liver 
transplant a 
n=74 
Hepatic decompensation b 
n=88 
Hepatocellular carcinoma b 
n=41 
Multivariable Multivariable Multivariable 
HR (95% CI) P sHR (95% CI) P sHR (95% CI) P 
Cirrhosis (yes) 6.34 (2.23-18.03) <.01 6.57 (2.47-17.46) <.01 6.55 (1.40-31.3) <.01 
Gender (male) 1.87 (1.08-2.85) .04 1.09 0.29 7.28 (3.1-17.1) <.01 
Race/ethnicity       
  Asian Ref - Ref - Ref - 
  Non-Hispanic White 2.65 .13 2.20 .30 3.14 .07 
  Hispanic White 2.86 .10 2.55 .16 4.13 .11 
Age, y 1.03 (1.01-1.06) .01 0.98 .21 1.05 (1.01-1.10) .01 
GE varices (yes) 2.19 (1.13-3.71) <.01 1.99 (1.16-3.05) .01 - - 
Current smoking (yes) c 1.74 (1.03-2.98) .03 1.22 .39 2.11 (1.17-5.27) .01 
Type 2 diabetes (yes) c 3.33 (1.69-6.54) <.01 2.82 (1.54-5.15) <.01 4.72 (2.13-10.45) <.01 
BMI (kg/m2) 0.98 .40 0.97 .26 0.99 .82 
Hypertension (yes) 0.73 .39 0.85 .64 0.71 .43 
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History of vascular events (yes) 0.68 .34 0.91 .85 0.77 .69 
History of malignant neoplasm (yes) 1.40 .58 0.88 .87 0.91 .64 
Statin therapy (yes) 0.95 .89 0.73 .25 0.57 .20 
Glucose-lowering medications (yes) 0.68 .29 0.56 .12 0.74 .46 
Anti-hypertensive medications (yes) 0.65 .27 1.35 .40 0.66 .49 
Aspirin (yes) 0.54 .21 0.77 .70 0.58 .45 
INR 7.19 (3.09-16.7) <.01 4.34 (1.41-13.33) .01 1.58 .58 
Albumin (g/dl) 0.56 (0.30-0.91) .05 0.47 (0.26-0.88) .01 0.61 .23 
Total bilirubin (mg/dl) 1.62 (1.19-2.21) <.01 1.7 (1.4-2.1) <.01 1.45 .26 
AST/ALT 1.86 (1.12-3.09) .01 1.56 (1.03-2.98) .03 1.84 .14 
Platelets (x 109/L) 0.99 (0.98-0.99) .02 0.98 (0.97-0.99) .01 0.99 .36 
MELD score 1.10 (1.02-1.18) <.01 0.99 .54 0.96 .46 
Abbreviations: CTP, Child-Turcotte-Pugh; sHR, subhazard ratios; BMI, body mass index; MELD, Model for End-Stage Liver Disease; INR, 
international normalized ratio; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GE, gastroesophageal.  
Since all liver-related tests may reflect severity of liver disease, and important collinearity (high VIF) was found between them, each variable 
(INR, albumin, total bilirubin, platelets count and AST/ALT ratio) was evaluated on independent models. Likewise, MELD score and their 
individual components were included separately in different models to avoid redundancy.    
a Multivariable Cox regression models.  
b Multivariable competing risk regression models. 
c Included as a time-dependent covariate.  
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FIGURE LEGENDS 
Fig. 1. Flow of patients through the study. 
Fig. 2. Cox-model adjusted overall survival without transplant in the full cohort. a 
a Survival curves represent adjusted predictions calculated by the Cox proportional 
regression model adjusted by centers, calendar year of patient recruitment and baseline 
fibrosis.  
Fig. 3A. Cox-model adjusted overall survival without transplant according to 
races/ethnicities. a 
a Survival curves represent adjusted predictions calculated by the Cox proportional 
regression model and adjusted by center, calendar year of patient recruitment and baseline 
fibrosis.   
Spanish and Cuban people were represented as Hispanic Whites.  
Fig. 3B. Cox-model adjusted overall survival without transplant according to 
races/ethnicities. b 
b Survival curves represent adjusted predictions calculated by the Cox proportional 
regression model adjusted by center, calendar year of patient recruitment, baseline fibrosis 
and CTP score. 
Spanish and Cuban people were represented as Hispanic Whites.  
Fig. 4. Competing-risks adjusted cumulative incidence of a first major clinical event. a 
a Outcome curves represent adjusted predictions calculated by the competing-risk regression 
model adjusted by center and calendar year of patient recruitment.  
This outcome accounted for the first occurrence of a major clinical event (hepatic 
decompensation, HCC, vascular and non-hepatic malignancies) over time. 
Fig. 5. Association between alcohol intakea and outcomes in cirrhotic patients. 
(A) Cox-model adjusted overall survival without transplant. b 
b Survival curves represent adjusted predictions calculated by the Cox proportional 
regression model adjusted by center and calendar year of patient recruitment.  
(B) Competing-risks adjusted cumulative incidence of HCC development. c 
c Cumulative incidences of HCC represent adjusted predictions calculated by the competing-
risk regression model adjusted by center and calendar year of patient recruitment.  
(C) Competing-risks cumulative incidence of the first hepatic decompensation. d 
d Cumulative incidences of hepatic decompensation represent adjusted predictions 
calculated by the competing-risk regression model adjusted by center and calendar year 
of patient recruitment.   
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    a Alcohol intake was analyzed as a time-varying covariate. 
Fig. 6. Cox-model adjusted overall survival without transplant by fibrosis severity. a 
a Survival curves represent adjusted predictions calculated by the Cox proportional 
regression model adjusted by center and calendar year of patient recruitment.  
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Assessed for eligibility (n=512) 
Excluded (n=54) 
• Not meeting inclusion criteria (n=54) 
- CTP ≥7 or MELD ≥ 15 (n=19) or platelets <100,000 mm3 (n=4) or total 
bilirubin > 3.0 mg/dL (n=6) or INR > 2 (n=7).  
- Diagnosis of HCC at baseline or within 6 months’ follow-up (n=3) 
- History of bariatric surgery (n=2) 
- Secondary causes of NAFLD or chronic liver diseases (n=13) 
 
Mean of follow-up: 5.5 (range, 2.7-8.2) y 
Min: 1 year, Max: 10 
880 person-years of follow-up. 
Cumulative survival or LTx 
   1 year: 100% 
   3 years: 99% 
   5 years: 98% 
   7 years: 96% 
   10 years: 93% 
   Lost to follow-up: 1 
Bridging fibrosis (n=159) Compensated cirrhosis CTP A5 (n=222) 
 
Included (n=458) 
Mean of follow-up: 5.5 (range, 2.7-9.1) y 
Min: 1 year, Max: 10 
1216 person-years of follow-up. 
Cumulative survival or LTx 
   1 year: 100% 
   3 years: 98% 
   5 years: 94% 
   7 years: 87% 
   10 years: 74% 
   Lost to follow-up: 3 
Compensated cirrhosis CTP A6 (n=77) 
 
Mean of follow-up: 5.3 (range, 2.4-7.8) y 
Min: 1 year, Max: 10 
406 person-years of follow-up. 
Cumulative survival or LTx 
   1 year: 96% 
   3 years: 88% 
   5 years: 72% 
   7 years: 47% 
   10 years: 19% 
   Lost to follow-up: 0 
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